DiaMedica Therapeutics, Inc. (DMAC)
8.18
+0.16
(+2.00%)
USD |
NASDAQ |
Nov 20, 10:36
DiaMedica Therapeutics Cash from Investing (Quarterly) : 10.25M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 10.25M |
| June 30, 2026 | 8.214M |
| March 31, 2026 | -2.114M |
| December 31, 2025 | 8.147M |
| September 30, 2025 | -26.20M |
| June 30, 2025 | 9.232M |
| March 31, 2025 | 6.622M |
| December 31, 2024 | 5.039M |
| September 30, 2024 | -5.535M |
| June 30, 2024 | 4.673M |
| March 31, 2024 | 4.208M |
| December 31, 2023 | 6.392M |
| September 30, 2023 | 1.184M |
| June 30, 2023 | -28.22M |
| March 31, 2023 | 2.509M |
| December 31, 2022 | 4.371M |
| September 30, 2022 | 1.970M |
| June 30, 2022 | 2.509M |
| March 31, 2022 | 2.214M |
| December 31, 2021 | -8.630M |
| September 30, 2021 | -12.79M |
| June 30, 2021 | 1.004M |
| March 31, 2021 | -0.009M |
| December 31, 2020 | 0.4203M |
| September 30, 2020 | -14.27M |
| Date | Value |
|---|---|
| June 30, 2020 | 2.541M |
| March 31, 2020 | -5.301M |
| December 31, 2019 | 1.025M |
| September 30, 2019 | 2.938M |
| June 30, 2019 | 3.037M |
| March 31, 2019 | -10.93M |
| December 31, 2018 | |
| September 30, 2018 | -0.0205M |
| June 30, 2018 | -0.0096M |
| March 31, 2018 | -0.032M |
| December 31, 2017 | -0.0149M |
| September 30, 2017 | -0.0042M |
| June 30, 2017 | -0.0028M |
| March 31, 2017 | 0.00 |
| December 31, 2016 | |
| September 30, 2016 | -0.0023M |
| June 30, 2016 | -0.0033M |
| March 31, 2016 | 0.0027M |
| December 31, 2015 | -0.0025M |
| September 30, 2015 | -0.0011M |
| June 30, 2015 | 0.0003M |
| March 31, 2015 | -0.0022M |
| December 31, 2014 | 0.0014M |
| September 30, 2014 | -0.005M |
| June 30, 2014 | -0.0115M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 203.86M |
| Nektar Therapeutics | 66.90M |
| Fortress Biotech, Inc. | -0.007M |
| ACADIA Pharmaceuticals, Inc. | -86.15M |
| Alnylam Pharmaceuticals, Inc. | -311.74M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.641M |
| Cash from Financing (Quarterly) | 0.1097M |
| Free Cash Flow | -33.68M |
| Free Cash Flow Per Share (Quarterly) | -0.1604 |
| Free Cash Flow to Equity (Quarterly) | -8.623M |
| Free Cash Flow to Firm (Quarterly) | -8.651M |
| Free Cash Flow Yield | -7.63% |